OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of CUVITRU™ [Immune Globulin ...

The global immunoglobulin market is set to grow at a 6.7% CAGR from 2025 to 2033, driven by rising autoimmune disorders and immunodeficiencies. Innovations in plasma technology and increasing use in ...

- Hizentra ® is the #1 immune globulin prescribed for Primary Immunodeficiency (PI) in the U.S. - Hizentra is the first and only subcutaneous immune globulin (SCIg) treatment approved for Chronic ...

KING OF PRUSSIA, Pa., Aug. 9, 2021 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Task Force ...

In patients with inborn errors of immunity who are prone to viral infections, immunoglobulin replacement therapy (IRT) administered via the conventional subcutaneous route showed lower viral infection ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA ® [Immune Globulin ...

Despite a pair of clinical misfires in 2023, argenx has stuck by the thesis that its star drug Vyvgart, also known as efgartigimod, can tackle a wide array of autoimmune diseases linked to ...